Influence of Breviscapine on Memory and Antioxidation Ability in Rats with Alzheimer′s Disease
Author information+
Department of Pharmacy， The Third Affiliated Hospital of Guangzhou Medical College， Guangzhou 510150， China
{{custom_zuoZheDiZhi}}
{{custom_authorNodes}}
{{custom_bio.content}}
{{custom_bio.content}}
{{custom_authorNodes}}
Collapse
History+
Received
Revised
Published
2011-05-20
2011-05-20
2012-03-10
Issue Date
2012-04-14
Abstract
OBJECTIVE To study the effect of breviscapine on memory and antioxidation ability in Aβ42-induced Alzheimer’s disease (AD) rat model. METHODS AD rat model was established by intracerebroventricular injection of Aβ42. Besides， sham-operated mice served as control group. The learning and memory ability was determined by Morris water maze test. The activities of glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) and the content of Malondialdehyde (MDA) in brain tissue were measured with spectrophotometer. RESULTS Compared with control group， AD model significantly prolonged the latency of searching the hidden platform in directional swimming test， and decreased time spent in swimming in the target quadrant in probe test. Breviscapine dose-dependently shortened the latency of searching the hidden platform in directional swimming test， and increased the time spent swimming in the target quadrant in probe test. The activities of GSH-Px and SOD were decreased， and the MDA content was increased in AD model rats.In breviscapine treatment groups， the activities of GSH-Px and SOD heightened and MDA content decreased， and there was significant difference compared with AD model group. CONCLUSION Breviscapine can dose-dependently ameliorate the impaired learning and memory function of AD model rats and improve antioxidation ability.
Influence of Breviscapine on Memory and Antioxidation Ability in Rats with Alzheimer′s Disease[J]. Chinese Pharmaceutical Journal, 2012, 47(5): 347-350
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] FERRIC C， PRINCE M， BRAYNE C， et al. Global prevalence of dementia： a delphi consensus study [J]. Lancet， 2005， 366(9503)： 2112-2117. [2] WANG J M， LV X Y， WANG C H. Clinical study of breviscapine treated the patients with vascular dementia [J]. J Weifang Med Coll(潍坊医学院学报)， 2007，29(5)：428-430. [3] ZHE X， CHAO L， FANG W， et al. Protective effects of breviscapine on ischemic vascular dementia in rats [J]. Biol Pharm Bull， 2006，29(9)： 1880-1885. [4] XIA L， WEI W， LIN H， et al. Experimental study on protective effect of breviscap ine in the liver of diabeticrats [J]. Chin Pharmacol Bull（中国药理学通报）， 2004， 20 (6)： 664-668. [5] LOO D T， COPANI A， PIKE C J， et al. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons [J]. Proc Natl Acad Sci USA， 1993， 90（17）： 7951-7955. [6] POEGGELER B， MIRAVALLE L， ZAGORSKI M G， et al. Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide [J]. Biochemistry， 2001， 40（49）： 14995-15001. [7] ZAWIA N H， LAHIRI D K， CARDOZO-PELAEZ F. Epigenetics， oxidative stress， and Alzheimer disease [J]. Free Radic Biol Med， 2009， 46(9)：1241-1249. [8] ZHOU L S， ZHU S X, WANG L S. Influence of Boschniakiarossicaextract on the content of Ach and the capability of learning and memory in Alzheimer’s disease rats [J]. Chin Pharm J (中国药学杂志)，2009，29(3)：1980-1983. [9] PRATICO D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy： lights and shadows [J]. Ann N Y Acad Sci， 2008， 1147（12）： 70-78. [10] MELO J B， SOUSA C， GARCAO P， et al. Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons [J]. Eur J Neurosci， 2009， 29（3）： 455-464.
PDF(1021 KB)
